TD Cowen Reiterates Buy Rating on uniQure BV (QURE)

TD Cowen analyst Joseph Thome reiterated a Buy rating and {REMOVEPT} price target on uniQure BV (NASDAQ: QURE)

The analyst comments: "The Ph. I/II study of AMT-130 in Huntington's disease hit the prespecified primary endpoint with a 75% slowing of disease progression by cUHDRS vs. a propensity-score matched external control using the FDA-aligned statistical analysis plan (p=0.003). These results exceeded expectations, as physicians viewed 30% slowing of disease progression as clinically meaningful, while we think investors had a higher bar of 50-60% given the prior 2-yr data.

Impressively, there was a statistically significant 60% slowing of disease progression as measured by TFC (p=0.033), which has been hinted as a favored endpoint by the FDA for confirmation of therapeutic activity as it captures disease burden on daily activity. There was an 8.2% mean reduction of CSF NfL from baseline vs. a predicted 30-45% increase in untreated HD patients.

Importantly, AMT-130 was generally well-tolerated with a manageable safety profile, with no new drug-related SAEs observed since December 2022. The most common AEs were related to the surgical administration of AMT-130, and all resolved. Given recent unfortunate safety events and deaths from other gene therapy programs, we and mgmt continue to highlight that AMT-130's safety profile is differentiated."

For an analyst ratings summary and ratings history on uniQure BV click here. For more ratings news on uniQure BV click here.

Shares of uniQure BV closed at $13.66 yesterday.

You May Also Be Interested In

• Stripe, Advent In Talks To Buy Paypal - WSJ
• Jane Street Took $15 Billion Hit In July Tied To Situational Awareness - Reuters
• Cantor Fitzgerald Reiterates Overweight Rating on Merlin Labs (MRLN)